Literature DB >> 15322940

Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila.

C Carbon1, R Nusrat.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322940     DOI: 10.1007/s10096-004-1152-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  14 in total

1.  Lung concentrations of telithromycin after oral dosing.

Authors:  O A Khair; J M Andrews; D Honeybourne; G Jevons; F Vacheron; R Wise
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

2.  New outbreak of legionnaires' disease in the United Kingdom.

Authors:  Carol Joseph
Journal:  BMJ       Date:  2002-08-17

3.  Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Preira; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

4.  Efficacy and safety of telithromycin in community-acquired pneumonia.

Authors:  Dirkie J Van Rensburg; Peter A Matthews; Bruno Leroy
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

5.  Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.

Authors:  L Hagberg; A Torres; D van Rensburg; B Leroy; M Rangaraju; E Ruuth
Journal:  Infection       Date:  2002-12       Impact factor: 3.553

6.  Telithromycin.

Authors:  J A Balfour; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.

Authors:  M R Hammerschlag; P M Roblin; C M Bébéar
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

8.  Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.

Authors:  J Pullman; J Champlin; P S Vrooman
Journal:  Int J Clin Pract       Date:  2003-06       Impact factor: 2.503

9.  Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.

Authors:  L Hagberg; C Carbon; D J van Rensburg; C Fogarty; L Dunbar; J Pullman
Journal:  Respir Med       Date:  2003-06       Impact factor: 3.415

10.  Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia.

Authors:  C Carbon; S Moola; I Velancsics; B Leroy; M Rangaraju; P Decosta
Journal:  Clin Microbiol Infect       Date:  2003-07       Impact factor: 8.067

View more
  2 in total

Review 1.  Treatment of Legionnaires' disease.

Authors:  Guy W Amsden
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.